Critical Outcome Technologies, Inc. (COTI) has entered into a drug discovery agreement with an undisclosed pharmaceutical company under which COTI will use CHEMSAS, its artificial intelligence drug discovery system, to identify and optimize several small molecules against an undisclosed target.   COTI will be responsible for the discovery, profiling and optimization of targeted drug candidates for evaluation by the sponsor. If a suitable target is selected, the companies will execute a license a...